Sprint Bioscience (Sweden) Today
| SPRINT Stock | SEK 1.82 0.02 1.09% |
Performance9 of 100
| Odds Of DistressLess than 39
|
Sprint Bioscience is trading at 1.82 as of the 1st of December 2024, a 1.09 percent decrease since the beginning of the trading day. The stock's open price was 1.84. Sprint Bioscience has about a 39 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Sprint Bioscience AB are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of September 2024 and ending today, the 1st of December 2024. Click here to learn more.
Sprint Bioscience AB develops pharmaceutical products in the areas of cancer and metabolism. Sprint Bioscience AB was founded in 2009 and is based in Huddinge, Sweden. Sprint Bioscience operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange.. The company has 69.8 M outstanding shares. More on Sprint Bioscience AB
Moving together with Sprint Stock
Moving against Sprint Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Sprint Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Sprint Bioscience's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Sprint Bioscience or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers - Specialty & Generic, Healthcare (View all Sectors) |
Sprint Bioscience AB (SPRINT) is traded on Stockholm Exchange in Sweden and employs 34 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 53.17 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Sprint Bioscience's market, we take the total number of its shares issued and multiply it by Sprint Bioscience's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Sprint Bioscience operates under Healthcare sector and is part of Drug Manufacturers - Specialty & Generic industry. The entity has 69.8 M outstanding shares.
Sprint Bioscience AB has accumulated about 13.82 M in cash with (40.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.19.
Check Sprint Bioscience Probability Of Bankruptcy
Ownership AllocationSprint Bioscience shows a total of 69.8 Million outstanding shares. Sprint Bioscience maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Sprint Ownership Details
Sprint Bioscience Risk Profiles
Although Sprint Bioscience's alpha and beta are two of the key measurements used to evaluate Sprint Bioscience's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.37 | |||
| Semi Deviation | 4.22 | |||
| Standard Deviation | 4.91 | |||
| Variance | 24.07 |
Sprint Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Sprint Bioscience without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Valuation Now
Equity ValuationCheck real value of public entities based on technical and fundamental data |
| All Next | Launch Module |
Sprint Bioscience Corporate Directors
| AnneMarie Wenthzel | Director of Sales and Marketing | Profile | |
| Martin Andersson | Founder and Director of Discovery Projects | Profile | |
| Pr Nordlund | Founder and Director | Profile | |
| Jessica MSc | Founder, Director of Medicinal Chemistry and Director | Profile |
Other Information on Investing in Sprint Stock
Sprint Bioscience financial ratios help investors to determine whether Sprint Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sprint with respect to the benefits of owning Sprint Bioscience security.